Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Spondyloarthritis family · A closer look at PsA

PsA treatment: benefits, risks and the cost of waiting

A practical way to weigh treatment concerns alongside the consequences of persistent active disease.

Olga Goodman, MD · Sources checked 27 September 2026

Chapter 6 of 21

The essentials

The decision includes two sides: what a medicine may cause, and what inadequately controlled disease may do. Agree on a timely plan that fits your risks and goals.

Why effective treatment should not drift indefinitely

Persistent inflammation can damage joints and limit function. Treatment aims to control inflammation, preserve abilities and improve daily life; already established damage may not fully reverse. The course differs between people, so neither a frightening photograph nor a mild first visit predicts everyone’s future. 3

A considered decision can take time for assessment, infection screening or a second opinion. The useful distinction is whether there is a clear next step and review date. Repeated postponement while disease remains active deserves a specific discussion.

Compare realistic options

These are illustrative decision situations, not prescriptions. The comparison is not “medicine versus no risk.” Ask what is likely to happen with each reasonable option and how uncertainty will be managed.

Compare realistic options
SituationUseful next discussion
Active swelling persists; treatment is repeatedly delayedWhat damage or functional loss are we trying to prevent, and what specific barrier can we address now?
A medicine helps, but nausea is disrupting lifeCan the dose, route or supportive plan be adjusted, or is a different treatment needed?
A serious personal risk changes the balanceWhich alternative mechanism or monitoring plan better fits this history?
Symptoms continue despite good inflammation controlAssess other pain mechanisms and rehabilitation needs before assuming more immune suppression will help.

Separate tolerability from serious harm

Nausea that disrupts a working day matters, even when it is not medically dangerous. A rare serious event matters for a different reason. Ask which effects are common and manageable, which require a call and which require urgent care. Report symptoms rather than assuming every new problem comes from the drug.

Personal factors can change the balance: previous serious infection, cardiovascular or clotting disease, smoking, cancer history, liver or kidney problems, pregnancy plans and other medicines. A warning in a leaflet is a reason for a focused discussion, not a prediction that the event will occur. JAK inhibitors need a particularly explicit discussion of their labelled risks. 7

What monitoring can and cannot do

Screening, vaccinations, laboratory checks and agreed infection instructions reduce avoidable problems; they cannot remove every risk. Ask who reviews results, when you will hear back and what to do if a test or prescription is delayed. 3, 4, 8

Keep a short record of the benefit as well as difficulties: swelling, morning stiffness, walking, sleep, work and a task that matters to you. Otherwise the decision may focus on a side-effect list without documenting what treatment has made possible.

Ask for numbers that can be compared

When a percentage is offered, ask: among whom, over what period, compared with what, and how many people in each group? Relative increases without baseline frequencies can sound much larger or smaller than the absolute difference. Results from different studies cannot automatically rank medicines.

For example, “twice the risk” is incomplete without the starting risk and timeframe. This chapter does not assign a personal risk percentage; your history and the relevant product evidence are needed.

Turn fear into a reviewable decision

Name the concern precisely: cancer, infection, nausea, dependence, injections, cost or uncertainty about the diagnosis. Ask the team to explain the expected benefit, alternatives, monitoring and a fallback plan. You can bring a trusted person and request written instructions.

If you decide to wait, clarify what will happen meanwhile, what change should prompt contact and when the decision will be revisited. You do not have to accept uncontrolled symptoms as the price of being cautious.

Shields up: infections and vaccines on treatment — Free after registration →

Methotrexate, the friendly way — Open demo · no registration →

Go deeper

Shared decisions do not require certainty

Clinical evidence estimates average outcomes in groups. A treatment decision applies that evidence to a particular person, then checks what actually happens. A written target and review date make uncertainty manageable: continue when benefit and tolerability are acceptable; reassess when they are not.

A useful question is: “What evidence would make us change this plan?” It invites discussion of both insufficient control and adverse effects without presenting either treatment or waiting as harmless.

Questions for your visit

  1. What is the likely benefit for my active manifestations?
  2. Which risks matter most in my medical history?
  3. What are the consequences of delaying in my situation?
  4. Which findings would make us change the plan?

When to seek urgent help

A painful red eye, light sensitivity or a sudden change in vision needs urgent assessment. A newly hot, swollen joint, especially with fever or feeling unwell, also needs prompt assessment.

Sources & evidence notes

Sources checked 27 September 2026

Drug approvals and availability vary by country. Regulatory updates are identified separately from older recommendations.

  1. NIAMS. Psoriatic arthritis: diagnosis, treatment and steps to take.
  2. American College of Rheumatology. Methotrexate: patient information. February 2025.
  3. FDA. JAK inhibitors: warnings about serious cardiovascular events, cancer, thrombosis and death.
  4. FDA. Sotyktu (deucravacitinib): US prescribing information, revised March 2026.

Educational information for patients and caregivers. This personal publication is not the clinic portal and does not provide individual diagnosis or treatment. Discuss medication changes with your own care team.

© 2026 Olga Goodman, MD · A RheumaView publication. Copying without attribution prohibited.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: PsoriasisPsoriatic arthritisSpondyloarthritis